Cardiovasc Prev Pharmacother > v.6(4)

5 results

103 Sodium-glucose cotransporter 2 inhibitors in cardiocerebrovascular disease
Jin Joo Park
KMSID: 1516088709   Cardiovasc Prev Pharmacother. 2024;6(4):103-108.   Published online 2024 October 31    DOI: http://dx.doi.org/10.36011/cpp.2024.6.e16
      
109 Moyamoya disease: insights into the clinical implications of the RNF213 gene
Taedong Ok
KMSID: 1516088711   Cardiovasc Prev Pharmacother. 2024;6(4):109-115.   Published online 2024 October 31    DOI: http://dx.doi.org/10.36011/cpp.2024.6.e14
      
116 Paradigm shift from glucocentric to organ protection for the management of hyperglycemia in patients with type 2 diabetes
Jie-Eun Lee, Jong Chul Won
KMSID: 1516088708   Cardiovasc Prev Pharmacother. 2024;6(4):116-122.   Published online 2024 October 31    DOI: http://dx.doi.org/10.36011/cpp.2024.6.e15
      
123 Relationship between autonomic and peripheral neuropathies and cardiovascular outcomes in diabetes
Jae-Seung Yun
KMSID: 1516088712   Cardiovasc Prev Pharmacother. 2024;6(4):123-127.   Published online 2024 October 31    DOI: http://dx.doi.org/10.36011/cpp.2024.6.e17
      
128 Use of dual-energy x-ray absorptiometry for body composition in chronic disease management
Tae Nyun Kim
KMSID: 1516088710   Cardiovasc Prev Pharmacother. 2024;6(4):128-134.   Published online 2024 October 31    DOI: http://dx.doi.org/10.36011/cpp.2024.6.e13
      
Articles from Cardiovascular Prevention and Pharmacotherapy are provided here courtesy of Korean Society of Cardiovascular Disease Prevention; Korean Society of Cardiovascular Pharmacotherap